Peran Janus Kinase inhibitor pada Penyakit Autoimun
DOI:
https://doi.org/10.55175/cdk.v49i12.327Keywords:
autoimun, imunosupresif, methotrexate, TNFi-biologics, non-TNFi-biologics, Janus Kinase inhibitor, tofacitinib, baricitinib, upadacitinib, filgotinibAbstract
Modalitas pengobatan utama penyakit autoimun adalah obat immunosupresif, misalnya methotrexate, TNFi-biologics, non-TNFi-biologics, dan yang paling baru adalah Janus Kinase inhibitor. Mekanisme kerja Janus Kinase inhibitor adalah dengan cara menghambat kerja enzim Janus Kinase pada proses signaling respons imun. Dalam artikel ini akan dibahas beberapa obat Janus Kinase inhibitor seperti: tofacitinib, baricitinib, upadacitinib, dan filgotinib, serta peran obat-obat ini pada pengobatan penyakit autoimun. The main treatment modality for autoimmune disease is immunosuppressive drugs, eg methotrexate, TNFi-biologics, non-TNFi-biologics, and most recently Janus Kinase inhibitors. The mechanism of action of Janus Kinase inhibitor drugs is by inhibiting the action of the Janus-Kinase enzyme in the signaling process of the immune response. This article will discuss several Janus Kinase inhibitor drugs such as: tofacitinib, baricitinib, upadacitinib, and filgotinib, as well as their role in the treatment of autoimmune diseases.Downloads
References
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021;157(8):940–6.
Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19.
Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):269–81.
Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2017;15(6):857–63.
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatol Oxf Engl. 2017;56(11):1945–61.
Richard-Eaglin A, Smallheer BA. Immunosuppressive/Autoimmune Disorders. Nurs Clin North Am. 2018;53(3):319–34.
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii111-115.
McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.
Padda IS, Bhatt R, Parmar M. Tofacitinib. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK572148/
Ahmad A, Zaheer M, Balis FJ. Baricitinib. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK572064/
Padda IS, Bhatt R, Parmar M. Upadacitinib. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Jul 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK572088/
Tarrant JM, Galien R, Li W, Goyal L, Pan Y, Hawtin R, et al. Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. Rheumatol Ther. 2020;7(1):173–90.
EMA. Jyseleca [Internet]. European Medicines Agency. 2020 [cited 2022 Jul 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca
Rheumatoid Arthritis (RA) [Internet]. [cited 2022 Jul 9]. Available from: https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Rheumatoid-Arthritis
Rekomendasi RA – Diagnosis dan Pengelolaan Artritis Reumatoid – Perhimpunan Reumatologi Indonesia [Internet]. [cited 2022 Jul 9]. Available from: https://reumatologi.or.id/rekomendasi-ra-diagnosis-dan-pengelolaan-artritis-reumatoid/
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet Lond Engl. 2017;390(10093):457–68.
Wang F, Sun L, Wang S, Davis JM, Matteson EL, Murad MH, et al. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Mayo Clin Proc. 2020;95(7):1404–19.
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–86.
Tian F, Chen Z, Xu T. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019;47(6):2342–50.
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol Hoboken NJ. 2019;71(1):5–32.
Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902.
Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–61.
Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, et al. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. J Clin Pharm Ther. 2022;47(7):851–9.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
